ACROBiosystems is committed to accelerating the research, development, approval, and commercialization of infectious disease vaccines. With this idea, Virus is specially designed for virus research!
Bringing together core R&D tools for RSV, rabies, influenza, shingles, Ebola, Zika and other viruses, providing high-quality antigens, antibodies, ELISA kits, etc., ACROBiosystems is willing to work together with biopharmaceutical companies, blocking the spread of viruses.
ACROBiosystems has accumulated mature technology and experience in viruses and vaccines. Since the COVID-19 outbreak, we continued to develop core reagents for other infectious virus research, vaccine, and therapeutic drug development based on its high-quality platform. We will continue to monitor the development of infectious diseases worldwide, aiming to provide core reagents for accelerating the development and clinical trials of vaccines and therapeutic drugs.
Image credit: ACROBiosystems
ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Their mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. They supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, ACROBiosystems delivers solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. ACROBiosystems empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.